

Bicara Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

January 6, 2022

CAMBRIDGE, Mass., January 6, 2022 – Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to elicit a potent and durable immune response in the tumor microenvironment, today announced that Claire Mazumdar, Ph.D., M.B.A., Chief Executive Officer of Bicara Therapeutics, will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference, to be held virtually January 10-13, 2022.

Presentation details:

Date: Wednesday, January 12, 2022

Time: 8:00 a.m. ET

About Bicara Therapeutics:

Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of immunotherapy. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy. Bicara's lead asset, BCA101, a first-in-class EGFR / TGF- β -trap bifunctional antibody, is currently enrolling patients in a Phase 1/2 study. Bicara's experienced team brings deep expertise across immunology, oncology, clinical development, business development and operational strategy.

Contacts:

Investors

Sarah McCabe

Stern Investor Relations, Inc.

sarah.mccabe@sternir.com

212-362-1200

Media

Chris Railey

Ten Bridge Communications

chris@tenbridgecommunications.com

617-834-0936